@article{oai:sapmed.repo.nii.ac.jp:00014907,
 author = {丹田, まり子 and 今井, 浩三},
 issue = {2},
 journal = {札幌医学雑誌 = The Sapporo medical journal, The Sapporo medical journal},
 month = {Apr},
 note = {The recent development of hybridoma technology, providing monoclonal antibodies （MoAb） of predefined specificity, has opened a new field in tumor immunology. MoAbs are currently being assessed for their usefulness as immunotherapeutic agents, either alone, or coupled with drugs, toxins, or to radioactive compounds. In this study, monoclonal antibody MT008 （IgG3） that reacts with human colonic cancer, was conjugated with purothionin （SP-H） having a molecular weight of 5500 daltons. The MoAb conjugated with SP-H suppressed colorectal carcinoma cells in vitro. In vivo, this immunoconjugate suppressed the growth of colorectal carcinoma in nude mice as evidenced by a greater number of survival days and smaller volume of tumors in the treated animals. In another study, monoclonal antibody S1 （IgG2a） that reacted with human hepatocellular carcinoma, mediated no tumor suppression in vitro, when used alone, but mediated ADCC activity against human cultured hepatocellular carcinoma cell in conjunction with murine splenocytes. In vivo, MoAb S1 alone suppressed the growth of hepatocellular carcinoma cells in nude mice as evidenced by a greater number of survival days and a smaller volume of tumors. 125I-labeled MoAb S1 significantly accumulated to this tumor in nude mice and mononuclear cells were infiltrated into the tumor masses. These results suggest that the inhibition of tumor growth might be mediated by an antibody dependent cell-mediated cytotoxicity.},
 pages = {247--261},
 title = {担癌ヌードマウスにおけるモノクローナル抗体単独及び抗体・薬物結合体の治療効果に関する研究},
 volume = {56},
 year = {1987}
}